Copay accumulator programs have only one purpose; increase profits for payers. Patients don’t gain an advantage, nor do manufacturers. On...
Year: 2022
Fractures in The 340B Program
The 340B Program remains controversial. Hospitals and other Covered Entities (providers qualified to buy drugs at 340B prices) that benefit...
The Impact of Medicare Price Negotiations
The Inflation Reduction Act (IRA) passed on August 16th, 2022 brings big changes for the pharmaceutical industry. On August 31st...
The Part D Squeeze
[DISCLAIMER: This isn’t a legal analysis. We’ve simplified provisions in the law where we could while still describing the intent...
“Negotiating” A Drug Deal with Medicare
[DISCLAIMER: This isn’t a legal analysis. We’ve simplified provisions in the law where we could while still describing the intent...
Shopping for Healthcare Deals
New price transparency rules set by the government are an opportunity to save money. Not for hospitals, not for payers,...
Are PBMs Actually Pharma’s Friends?
Pharmacy Benefit Managers (PBMs) have received a lot of negative publicity lately. Here is some more: A new whistleblower lawsuit...
A 3-way Tug-of-War Over Physician Practices
and its impact on pharmaPhysicians who own their own practices should feel honored! They are the focus of an ongoing...